📋 Table of Contents
As GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have become some of the most widely prescribed drugs in the country, a specific side effect has become its own widely discussed phenomenon: “Ozempic face,” the hollowed, aged appearance some people notice in their face after significant, rapid weight loss. The term was first coined by a New York dermatologist in 2023 and has since become a mainstream shorthand, even though the underlying phenomenon isn’t unique to GLP-1 medications specifically.
What Is “Ozempic Face”?
“Ozempic face” refers to facial volume loss and skin laxity that becomes noticeable after significant, often rapid, weight loss, resulting in hollowed cheeks or temples, more prominent nasolabial folds and wrinkles, and sagging around the jawline and under the eyes. Despite the branded name, it isn’t a direct pharmacological side effect of the medication itself; it’s a consequence of the rate and amount of fat loss the medication enables, and similar changes have long been observed in people who lose significant weight quickly through any method, including bariatric surgery.
Why It Happens: The Science of Facial Fat Loss
The face contains two distinct fat compartments: a superficial layer just under the skin and a deeper layer closer to the bone and muscle. Normal aging tends to primarily deplete the deep fat compartment. Research from Vanderbilt University found that GLP-1-driven weight loss disproportionately affects the superficial fat compartment instead, which may help explain why the resulting appearance looks distinctly different from ordinary age-related facial volume loss, even though the underlying cause, fat loss, is conceptually similar. The same research estimated roughly 9% midface volume loss for every 10 kilograms of total body weight lost, giving a rough sense of how directly the two are linked. Some researchers have also identified GLP-1 receptors in skin cells directly, raising the possibility that the medication may have some additional, still-unclear direct effects on skin beyond fat loss alone, though this remains an active area of study.
It’s also worth understanding that this isn’t strictly a GLP-1-specific phenomenon, even though the branded term suggests otherwise. Plastic surgeons have documented similar hollowing and skin laxity for decades in patients who lost significant weight quickly through other means, including bariatric surgery and very low-calorie diets, well before GLP-1 medications existed. What’s different this time is scale: because GLP-1 drugs have made rapid, substantial weight loss accessible to a far larger population than surgery ever did, a phenomenon that was previously a relatively niche concern among bariatric surgery patients and their surgeons has become common enough to earn its own widely recognized name and a dedicated cosmetic treatment market.
Who’s Most at Risk
Several factors appear to increase the likelihood of noticeable facial changes, and understanding your own individual risk factors can help set realistic expectations before starting treatment:
- Rate of weight loss. Faster weight loss appears to produce more pronounced facial changes than the same total amount of weight lost more gradually.
- Total amount of weight lost. Given the roughly linear relationship found in the Vanderbilt research, larger total weight loss is associated with more midface volume loss.
- Age. Older adults generally have less baseline skin elasticity, making visible sagging more likely at a given amount of fat loss compared to younger patients.
- Inadequate protein intake and lack of resistance training during the weight loss period, which increases the proportion of lean muscle lost alongside fat, including in the face.
Slower, more gradual weight loss is one of the most consistently recommended prevention strategies. Photo: Pexels
Evidence-Based Prevention Strategies
Dermatologists, plastic surgeons, and endocrinologists broadly agree on a similar set of first-line prevention strategies, best started at the beginning of GLP-1 treatment rather than after facial changes appear:
- Favor gradual weight loss where clinically appropriate (commonly cited as roughly 0.5–1 kg per week), discussed with your prescribing physician, since slower loss appears to be gentler on facial volume and skin.
- Prioritize protein intake at every meal to help protect lean muscle mass, since a meaningful share of weight lost on GLP-1 medications can come from muscle rather than fat if protein intake is inadequate.
- Add resistance training two to three times a week, which helps preserve muscle mass throughout the body, including supporting facial structure indirectly through overall lean mass preservation.
- Stay well hydrated, since adequate hydration supports skin elasticity and overall skin health during a period of significant body composition change.
- Use daily sunscreen, since UV damage independently accelerates collagen breakdown and will compound any skin laxity from weight loss.
High-protein shakes and collagen-support supplements to help protect muscle and skin during weight loss.
Treatment Options If It’s Already Happened
For people who already notice facial changes, dermatologic and cosmetic options exist, though they come with real cost and are not permanent fixes on their own. Hyaluronic acid dermal fillers can restore lost volume directly and are among the most commonly used first-line treatments. Biostimulatory fillers, such as poly-L-lactic acid or calcium hydroxylapatite-based products, work more gradually by stimulating the body’s own collagen production. Radiofrequency and microneedling treatments are used to improve skin tightness and texture, often in combination with filler for a more complete result. These treatments should be discussed with a board-certified dermatologist or plastic surgeon, since results and appropriate technique vary significantly by individual anatomy and the degree of volume loss. Cost is a real consideration: filler and biostimulatory treatments typically require repeat sessions to maintain results and are rarely covered by insurance since they’re considered cosmetic, so it’s worth having a clear conversation with a provider about a realistic maintenance schedule and total cost before starting any treatment plan.
Beyond the Face: Skin and Hair Changes Too
Facial volume loss isn’t the only appearance-related change reported by people on GLP-1 medications. Dry skin is a commonly reported change, likely related to more rapid fat loss and shifts in hydration status during significant weight loss. Hair thinning, generally temporary, has also been reported by some patients, a pattern seen historically with rapid weight loss from any cause and thought to be related to the physical stress of significant, fast body composition change triggering a temporary shift in the hair growth cycle. Interestingly, the picture for skin isn’t uniformly negative: a 2026 study published in Cureus that followed 110 semaglutide users over two years found that acne severity actually declined over the course of treatment for many participants, an effect researchers suggested may be linked to improvements in BMI, blood sugar, and insulin levels that often accompany GLP-1-driven weight loss. That study didn’t include a control group, so the researchers describe the relationship as still unclear rather than firmly established, but it’s a useful reminder that GLP-1-related appearance changes aren’t uniformly negative across every domain, even as facial volume loss remains a genuine and well-documented concern.
Keeping This in Perspective
It’s worth remembering that “Ozempic face” is a cosmetic side effect of a medication that, for many patients, is producing significant and clinically meaningful improvements in weight-related health conditions like type 2 diabetes, high blood pressure, and cardiovascular risk. It is not a dangerous medical complication, and for most patients it is manageable, and to some degree preventable, with the strategies above. Discussing pace of weight loss and prevention strategies with your prescribing physician at the start of treatment, rather than after changes appear, gives you the most options.
Frequently Asked Questions
Does Ozempic face happen to everyone who loses weight on GLP-1 medications?
No. The degree of facial change varies significantly based on rate and amount of weight loss, age, baseline skin elasticity, and how well muscle mass is preserved through protein intake and resistance training during treatment.
Is Ozempic face permanent?
Not necessarily. While the underlying fat loss is real, many of the visible effects can be improved with dermatologic treatments like fillers, biostimulators, and skin-tightening procedures, and some skin elasticity can also improve over time with good nutrition and skin care.
Can I prevent Ozempic face by losing weight more slowly?
Slower, more gradual weight loss (discussed with your prescribing physician) is one of the most consistently recommended prevention strategies, alongside adequate protein intake and resistance training to help preserve muscle and support facial structure.
Does Ozempic cause other skin or hair changes besides facial volume loss?
Yes. Some patients report dry skin and temporary hair thinning during rapid weight loss. Interestingly, a 2026 study also found acne severity declined over two years of semaglutide use in many participants, though researchers note the relationship isn’t yet fully understood.
References:
Leave a Reply